{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:11Z","timestamp":1794047351635,"version":"4.8.0"},"reference-count":59,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chronic myelogenous leukemia arises from the transformation of hematopoietic stem cells by the BCR-ABL oncogene. Though transformed cells are predominantly BCR-ABL-dependent and sensitive to tyrosine kinase inhibitor treatment, some BMPR1B+ leukemic stem cells are treatment-insensitive and rely, among others, on the bone morphogenetic protein (BMP) pathway for their survival via a BMP4 autocrine loop. Here, we further studied the involvement of BMP signaling in favoring residual leukemic stem cell persistence in the bone marrow of patients having achieved remission under treatment. We demonstrate by single-cell RNA-Seq analysis that a sub-fraction of surviving BMPR1B+ leukemic stem cells are co-enriched in BMP signaling, quiescence and stem cell signatures, without modulation of the canonical BMP target genes, but enrichment in actors of the Jak2\/Stat3 signaling pathway. Indeed, based on a new model of persisting CD34+CD38- leukemic stem cells, we show that BMPR1B+ cells display co-activated Smad1\/5\/8 and Stat3 pathways. Interestingly, we reveal that only the BMPR1B+ cells adhering to stromal cells display a quiescent status. Surprisingly, this quiescence is induced by treatment, while non-adherent BMPR1B+ cells treated with tyrosine kinase inhibitors continued to proliferate. The subsequent targeting of BMPR1B and Jak2 pathways decreased quiescent leukemic stem cells by promoting their cell cycle re-entry and differentiation. Moreover, while Jak2-inhibitors alone increased BMP4 production by mesenchymal cells, the addition of the newly described BMPR1B inhibitor (E6201) impaired BMP4-mediated production by stromal cells. Altogether, our data demonstrate that targeting both BMPR1B and Jak2\/Stat3 efficiently impacts persisting and dormant leukemic stem cells hidden in their bone marrow microenvironment.<\/jats:p>","DOI":"10.3324\/haematol.2019.232793","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T14:35:12Z","timestamp":1580394912000},"page":"111-122","source":"Crossref","is-referenced-by-count":45,"title":["The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission"],"prefix":"10.3324","volume":"106","author":[{"given":"Sandrine","family":"Jeanpierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawtar","family":"Arizkane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supat","family":"Thongjuea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Grockowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Geistlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Voeltzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Gonin-Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gandrillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck-Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Maguer-Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"17504","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, O'Brien S, Cortes JE. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myeloid leukemia are associated with excellent long-term prognosis. Cancer. 2003; 97(4):1033-1041.","DOI":"10.1002\/cncr.11223"},{"key":"17505","doi-asserted-by":"crossref","unstructured":"Simonsson B, Gedde-Dahl T, Markevarn B. Combination of pegylated IFNalpha2b with imatinib increases molecular response rates in patients with low- or intermediate- risk chronic myeloid leukemia. Blood. 2011; 118(12):3228-3235.","DOI":"10.1182\/blood-2011-02-336685"},{"key":"17506","doi-asserted-by":"crossref","unstructured":"Chu S, McDonald T, Lin A. Persistence of leukemia stem cells in chronic myeloid leukemia patients in prolonged remission with imatinib treatment. Blood. 2011; 118(20):5565-5572.","DOI":"10.1182\/blood-2010-12-327437"},{"key":"17507","doi-asserted-by":"crossref","unstructured":"Chomel J-C, Bonnet M-L, Sorel N. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011; 118(13):3657-3660.","DOI":"10.1182\/blood-2011-02-335497"},{"key":"17508","doi-asserted-by":"crossref","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronicphase chronic myeloid leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014; 32(5):424-430.","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"17509","doi-asserted-by":"crossref","unstructured":"Warfvinge R, Geironson L, Sommarin MNE. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017; 129(17):2384-2394.","DOI":"10.1182\/blood-2016-07-728873"},{"key":"17510","doi-asserted-by":"crossref","unstructured":"Giustacchini A, Thongjuea S, Barkas N. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017; 23(6):692-702.","DOI":"10.1038\/nm.4336"},{"key":"17511","doi-asserted-by":"crossref","unstructured":"Zhang B, Li L, Ho Y. Heterogeneity of leukemia-initiating capacity of chronic myeloid leukemia stem cells. J Clin Invest. 2016; 126(3):975-991.","DOI":"10.1172\/JCI79196"},{"key":"17512","doi-asserted-by":"crossref","unstructured":"Graham SM, Jorgensen HG, Allan E. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99(1):319-325.","DOI":"10.1182\/blood.V99.1.319"},{"key":"17513","doi-asserted-by":"crossref","unstructured":"Hamilton A, Helgason GV, Schemionek M. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012; 119(6):1501-1510.","DOI":"10.1182\/blood-2010-12-326843"},{"key":"17514","doi-asserted-by":"crossref","unstructured":"Houshmand M, Simonetti G, Circosta P. Chronic myeloid leukemia stem cells. Leukemia. 2019; 33(7):1543-1556.","DOI":"10.1038\/s41375-019-0490-0"},{"key":"17515","doi-asserted-by":"crossref","unstructured":"Agarwal P, Isringhausen S, Li H. Mesenchymal niche-specific expression of Cxcl12 controls quiescence of treatmentresistant leukemia stem cells. Cell Stem Cell. 2019; 24(5):769-784.e6.","DOI":"10.1016\/j.stem.2019.02.018"},{"key":"17516","doi-asserted-by":"crossref","unstructured":"Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996; 10(13):1580-1594.","DOI":"10.1101\/gad.10.13.1580"},{"key":"17517","doi-asserted-by":"crossref","unstructured":"Goldman DC, Bailey AS, Pfaffle DL, Masri AA, Christian JL, Fleming WH. BMP4 regulates the hematopoietic stem cell niche. Blood. 2009; 114(20):4393-4401.","DOI":"10.1182\/blood-2009-02-206433"},{"key":"17518","doi-asserted-by":"crossref","unstructured":"Hutton JF, Rozenkov V, Khor FSL, D'Andrea RJ, Lewis ID. Bone morphogenetic protein 4 contributes to the maintenance of primitive cord blood hematopoietic progenitors in an ex vivo stroma-noncontact co-culture system. Stem Cells Dev. 2006; 15(6):805-813.","DOI":"10.1089\/scd.2006.15.805"},{"key":"17519","doi-asserted-by":"crossref","unstructured":"Khurana S, Buckley S, Schouteden S. A novel role of BMP4 in adult hematopoietic stem and progenitor cell homing via Smad independent regulation of integrin-alpha4 expression. Blood. 2013; 121(5):781-790.","DOI":"10.1182\/blood-2012-07-446443"},{"key":"17520","doi-asserted-by":"crossref","unstructured":"Jeanpierre S, Nicolini FE, Kaniewski B. BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood. 2008; 112(8):3154-3163.","DOI":"10.1182\/blood-2008-03-145326"},{"key":"17521","doi-asserted-by":"crossref","unstructured":"Maguer-Satta V, Bartholin L, Jeanpierre S. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res. 2003; 282(2):110-120.","DOI":"10.1016\/S0014-4827(02)00013-7"},{"key":"17522","doi-asserted-by":"crossref","unstructured":"Zylbersztejn F, Flores-Violante M, Voeltzel T, Nicolini FE, Lefort S, Maguer-Satta V. The BMP pathway: a unique tool to decode the origin and progression of leukemia. Exp Hematol. 2018; 61:36-44.","DOI":"10.1016\/j.exphem.2018.02.005"},{"key":"17523","doi-asserted-by":"crossref","unstructured":"Raymond A, Liu B, Liang H. A role for BMP-induced homeobox gene MIXL1 in acute myeloid leukemia and identification of type I BMP receptor as a potential target for therapy. Oncotarget. 2014; 5(24):12675-12693.","DOI":"10.18632\/oncotarget.2564"},{"key":"17524","doi-asserted-by":"crossref","unstructured":"Voeltzel T, Flores-Violante M, Zylbersztejn F. A new signaling cascade linking BMP4, BMPR1A, DeltaNp73 and NANOG impacts on stem-like human cell properties and patient outcome. Cell Death Dis. 2018; 9(10):1011.","DOI":"10.1038\/s41419-018-1042-7"},{"key":"17525","doi-asserted-by":"crossref","unstructured":"Laperrousaz B, Jeanpierre S, Sagorny K. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood. 2013; 122(23):3767-3777.","DOI":"10.1182\/blood-2013-05-501460"},{"key":"17526","doi-asserted-by":"crossref","unstructured":"Toofan P, Irvine D, Hopcroft L, Copland M, Wheadon H. The role of the bone morphogenetic proteins in leukaemic stem cell persistence. Biochem Soc Trans. 2014; 42(4):809-815.","DOI":"10.1042\/BST20140037"},{"key":"17527","doi-asserted-by":"crossref","unstructured":"Gerber JM, Gucwa JL, Esopi D. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013; 4(5):715-728.","DOI":"10.18632\/oncotarget.990"},{"key":"17528","doi-asserted-by":"crossref","unstructured":"Toofan P, Busch C, Morrison H. Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal. Cell Death Dis. 2018; 9(9):927.","DOI":"10.1038\/s41419-018-0905-2"},{"key":"17529","doi-asserted-by":"crossref","unstructured":"Grockowiak E, Laperrousaz B, Jeanpierre S. Immature CML cells implement a BMP autocrine loop to escape TKI treatment. Blood. 2017; 130(26):2860-2871.","DOI":"10.1182\/blood-2017-08-801019"},{"key":"17530","doi-asserted-by":"crossref","unstructured":"Cosset E, Hamdan G, Jeanpierre S. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood. 2011; 117(5):1673-1676.","DOI":"10.1182\/blood-2009-11-254680"},{"key":"17531","doi-asserted-by":"crossref","unstructured":"Baccarani M, Deininger MW, Rosti G. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6):872-884.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"17532","doi-asserted-by":"crossref","unstructured":"Schallmoser K, Rohde E, Reinisch A. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods. 2008; 14(3):185-196.","DOI":"10.1089\/ten.tec.2008.0060"},{"key":"17533","doi-asserted-by":"crossref","unstructured":"Sheng Y, Ji Z, Zhao H. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells. Cell Prolif. 2019; 52(4):e12611.","DOI":"10.1111\/cpr.12611"},{"key":"17534","doi-asserted-by":"crossref","unstructured":"Richard A, Boullu L, Herbach U. Singlecell- based analysis highlights a surge in cellto- cell molecular variability preceding irreversible commitment in a differentiation process. PLoS Biol. 2016; 14(12):e1002585.","DOI":"10.1371\/journal.pbio.1002585"},{"key":"17535","doi-asserted-by":"crossref","unstructured":"Byron SA, Loch DC, Wellens CL. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer. 2012; 11:75.","DOI":"10.1186\/1476-4598-11-75"},{"key":"17536","doi-asserted-by":"crossref","unstructured":"Zhang W, Borthakur G, Gao C. The dual MEK\/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations. Cancer Res. 2016; 76(6):1528-1537.","DOI":"10.1158\/0008-5472.CAN-15-1580"},{"key":"17537","doi-asserted-by":"crossref","unstructured":"Babiker HM, Byron SA, Hendricks WPD. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Invest New Drugs. 2019; 37(4):636-645.","DOI":"10.1007\/s10637-018-0668-8"},{"key":"17538","doi-asserted-by":"crossref","unstructured":"Kitamura T, Tange T, Terasawa T. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol. 1989; 140(2):323-334.","DOI":"10.1002\/jcp.1041400219"},{"key":"17539","doi-asserted-by":"crossref","unstructured":"Abraham SA, Hopcroft LE, Carrick E. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016; 534(7607):341-346.","DOI":"10.1038\/nature18288"},{"key":"17540","doi-asserted-by":"crossref","unstructured":"Das B, Pal B, Bhuyan R. MYC regulates the HIF2alpha stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. Cancer Res. 2019; 79(16):4015-4025.","DOI":"10.1158\/0008-5472.CAN-18-2847"},{"key":"17541","doi-asserted-by":"crossref","unstructured":"Pellicano F, Scott MT, Helgason GV. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells. 2014; 32(9):2324-2337.","DOI":"10.1002\/stem.1748"},{"key":"17542","doi-asserted-by":"crossref","unstructured":"Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009; 41(7):783-792.","DOI":"10.1038\/ng.389"},{"key":"17543","doi-asserted-by":"crossref","unstructured":"Nievergall E, Ramshaw HS, Yong AS. Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014; 123(8):1218-1228.","DOI":"10.1182\/blood-2012-12-475194"},{"key":"17544","doi-asserted-by":"crossref","unstructured":"Carter BZ, Mak PY, Mu H. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med. 2016; 8(355):355ra117.","DOI":"10.1126\/scitranslmed.aag1180"},{"key":"17545","doi-asserted-by":"crossref","unstructured":"Hamilton A, Helgason GV, Schemionek M. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012; 119(6):1501-1510.","DOI":"10.1182\/blood-2010-12-326843"},{"key":"17546","doi-asserted-by":"crossref","unstructured":"Kuepper MK, Butow M, Herrmann O. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. Leukemia. 2019; 33(8):1964-1977.","DOI":"10.1038\/s41375-019-0427-7"},{"key":"17547","doi-asserted-by":"crossref","unstructured":"Eiring AM, Kraft IL, Page BD, O'Hare T, Gunning PT, Deininger MW. STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leuk Suppl. 2014; 3(Suppl 1):S5-S6.","DOI":"10.1038\/leusup.2014.3"},{"key":"17548","doi-asserted-by":"crossref","unstructured":"Gallipoli P, Cook A, Rhodes S. JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 2014; 124(9):1492-1501.","DOI":"10.1182\/blood-2013-12-545640"},{"key":"17549","doi-asserted-by":"crossref","unstructured":"Gleixner KV, Schneeweiss M, Eisenwort G. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica. 2017; 102(9):1519-1529.","DOI":"10.3324\/haematol.2016.163436"},{"key":"17550","doi-asserted-by":"crossref","unstructured":"Chakraborty SN, Leng X, Perazzona B, Sun X, Lin YH, Arlinghaus RB. Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myeloid leukemia. Genes Cancer. 2016; 7(5-6):201-208.","DOI":"10.18632\/genesandcancer.111"},{"key":"17551","doi-asserted-by":"crossref","unstructured":"Ying QL, Nichols J, Chambers I, Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell. 2003; 115(3):281-292.","DOI":"10.1016\/S0092-8674(03)00847-X"},{"key":"17552","doi-asserted-by":"crossref","unstructured":"Chen X, Xu H, Yuan P. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 2008; 133(6):1106-1117.","DOI":"10.1016\/j.cell.2008.04.043"},{"key":"17553","doi-asserted-by":"crossref","unstructured":"Nakashima K, Yanagisawa M, Arakawa H. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science. 1999; 284(5413):479-482.","DOI":"10.1126\/science.284.5413.479"},{"key":"17554","unstructured":"Bersenev A, Wu C, Balcerek J, Tong W. Lnk controls mouse hematopoietic stem cell selfrenewal and quiescence through direct interactions with JAK2. J Clin Invest. 2008; 118(8):2832-2844."},{"key":"17555","doi-asserted-by":"crossref","unstructured":"Balenci L, Wonders C, Coles BL, Clarke L, van der Kooy D. Bone morphogenetic proteins and secreted frizzled related protein 2 maintain the quiescence of adult mammalian retinal stem cells. Stem Cells. 2013; 31(10):2218-2230.","DOI":"10.1002\/stem.1470"},{"key":"17556","doi-asserted-by":"crossref","unstructured":"Andreu Z, Khan MA, Gonzalez-Gomez P. The cyclin-dependent kinase inhibitor p27 kip1 regulates radial stem cell quiescence and neurogenesis in the adult hippocampus. Stem Cells. 2015; 33(1):219-229.","DOI":"10.1002\/stem.1832"},{"key":"17557","doi-asserted-by":"crossref","unstructured":"Han X, Yu L, Chen Q. BMP4\/LIF or RA\/Forskolin suppresses the proliferation of neural stem cells derived from adult monkey brain. Stem Cells Int. 2017; 2017:7012405.","DOI":"10.1155\/2017\/7012405"},{"key":"17558","doi-asserted-by":"crossref","unstructured":"Bond AM, Peng CY, Meyers EA, McGuire T, Ewaleifoh O, Kessler JA. BMP signaling regulates the tempo of adult hippocampal progenitor maturation at multiple stages of the lineage. Stem Cells. 2014; 32(8):2201-2214.","DOI":"10.1002\/stem.1688"},{"key":"17559","doi-asserted-by":"crossref","unstructured":"Lee J, Kang S, Lilja KC. Signalling couples hair follicle stem cell quiescence with reduced histone H3 K4\/K9\/K27me3 for proper tissue homeostasis. Nat Commun. 2016; 7:11278.","DOI":"10.1038\/ncomms11278"},{"key":"17560","doi-asserted-by":"crossref","unstructured":"Sawala A, Scarcia M, Sutcliffe C, Wilcockson SG, Ashe HL. Peak BMP responses in the drosophila embryo are dependent on the activation of integrin signaling. Cell Rep. 2015; 12(10):1584-1593.","DOI":"10.1016\/j.celrep.2015.08.012"},{"key":"17561","doi-asserted-by":"crossref","unstructured":"Visavadiya NP, Keasey MP, Razskazovskiy V. Integrin-FAK signaling rapidly and potently promotes mitochondrial function through STAT3. Cell Commun Signal. 2016; 14(1):32.","DOI":"10.1186\/s12964-016-0157-7"},{"key":"17562","doi-asserted-by":"crossref","unstructured":"Mahon FX, Rea D, Guilhot J. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11):1029-1035.","DOI":"10.1016\/S1470-2045(10)70233-3"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9638\/70535","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9638\/70536","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9638\/70535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:55:52Z","timestamp":1794045352000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2019.232793","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,30]]}}}